Ajovy FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved September 14, 2018)
Brand name: Ajovy
Generic name: fremanezumab-vfrm
Dosage form: Injection
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Migraine Prevention
Ajovy (fremanezumab) is a fully-humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand indicated for the preventive treatment of migraine.
Development timeline for Ajovy
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.